AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01134094 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open reduction internal fixation of the ankle
Description: The specific procedure for each patient managed operatively, both in the observational study and the RCT, will be determined by the operating surgeon. Any adverse intra-operative or post-operative event will be recorded. This includes but is not limited to death, infection and neurovascular injury. Post operatively, all patients will be NWB (non weight bearing) and placed in a POP (plaster of paris) below knee cast or walking boot. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. The treating surgeon will review the patients after 10-14 days for a wound review, removal of sutures and change of cast to a fibreglass cast or walking boot (cam walker). The patient will be WBAT (weight bearing as tolerated) for a further 4 weeks.
Study NCT01134094 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non Operative
Description: Patients who are treated non-operatively will be treated with a walking boot and allowed WBAT. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. All patients will be reviewed between 7 and 14 days post injury with repeat x-rays by the treating surgeon.
Study NCT04327453 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: double antibiotic paste with XP-endo Finisher file
Description: XP-endo Finisher files (FKG Dentaire, La Chaux-de-Fonds, Switzerland). file will be used with an endodontic motor X-Smart (Dentsply Sirona, Ballaigues, Switzerland) in removal of double antibiotic paste
Study NCT04327453 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: double antibiotic paste with Irrisafe Ultrasonic tip
Description: passive ultrasonic irrigation (PUI) with an IrriSafe Ultrasonic tips (Acteon,France), which will be driven by an ultrasonic device (Newtron P5, Satelec, Acteongroup, Merignac, France) in removal of double antibiotic paste
Study NCT04327453 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: double antibiotic paste with side vented needle
Description: conventional syringe irrigation with side vented needle (prime Dent, India) in removal of double antibiotic paste
Study NCT02645409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTL38
Description: OTL38 is a folate analog conjugated with a fluorescent dye that emits light in the near infrared spectrum. This longer wavelength allows for deeper penetration of the fluorescent light through tissues with the potential to better image tumors beneath adipose tissue or deeper into organ parenchyma.
Study NCT02645409 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraoperative fluorescence imaging system
Study NCT03617523 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone Quadrivalent vaccine, 2018-2019 formulation
Description: Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
Study NCT03617523 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flublok Quadrivalent vaccine, 2018-2019 formulation
Description: Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
Study NCT03617523 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone High-Dose vaccine, 2018-2019 formulation
Description: Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
Study NCT03427164 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transjugular Intrahepatic Portosystemic Shunt
Description: The TIPS procedures creates an artificial shunt from the portal vein to the hepatic vein. TIPS allows blood from the congested portal circulation to bypass the fibrotic liver and directly enter the systemic circulation.
Study NCT00965185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: 20 mg PO QD for the first 3 months, followed by 40 mg PO QD for the final 9 months.
Study NCT00965185 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01963806 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone-supplemented iCBT
Description: The Internet-administered cognitive behavioural self-help program (iCBT) will be divided into 10 weekly, progressively available modules covering CBT and Acceptance and Commitment Therapy (ACT) conceptualisations of anxiety disorders, as well as more specific therapeutic techniques such as cognitive restructuring, exposure training, attention and breathing exercises and relapse prevention . Each module also includes writing exercises.~Also included is a tailored smartphone application. Briefly, the application allows the user to access, create and modify a personal database of behaviours and check-off these behaviours immediately when completed. Frequency of carried-out behaviours are recorded and displayed as statistics. The application also allows users to browse and search a database of behaviours uploaded by other study participants, providing both inspiration and a sense of social support.
Study NCT01963806 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapist support
Description: The role of the therapists will be to provide feedback on the written exercises of each treatment module, as well as to provide support and encouragement. As a rule of thumb, the therapists will devote 15 minutes per participant and week.
Study NCT01963806 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active waiting list
Description: Completes measurements at day 24 and 48 and at the end of the initial treatment period, otherwise no activity until crossover.
Study NCT01733953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 6-Months of Atorvastatin (Lipitor); 40mg, oral, once daily.
Study NCT01733953 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill (Placebo)
Description: 6-Months of placebo (sugar) pill; oral, once daily
Study NCT03972917 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transvaginal ultrasonographic examination
Description: Evaluation of endometrial thickness; myoma size and volume
Study NCT03134807 — intervention group
Intervention type: OTHER
Intervention: Observation prospective
Description: No intervention
Study NCT06109740 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: lactobacillus GG
Description: probiotic
Study NCT06109740 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: lactobacillus GG
Description: probiotic
Study NCT00674297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvastatin
Description: Fluvastatin 40 mg daily for 3 months
Study NCT02512952 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open flap debridement (OFD)
Description: Oral prophylaxis followed by Open flap debridement (OFD)
Study NCT02512952 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OFD with Platelet rich fibrin (PRF)
Description: Oral prophylaxis followed by Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement into the bone defect
Study NCT03243799 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group psychoeducation
Description: Educational group sessions for patients with depression and physical comorbidities in order to improve the degree of control of their illnesses
Study NCT02512952 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OFD with Titanium Platelet rich fibrin (TPRF)
Description: Oral prophylaxis followed by Open flap debridement (OFD) with Titanium Platelet rich fibrin (TPRF) placement into the bone defect
Study NCT03113786 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CLARIX™100
Description: CLARIX™100 is Amniox's processed and cryopreserved human amniotic membrane tissue retrieved from donated placental tissue after elective Cesarean Section delivery. Amniox's Amniotic Membrane is designated by the FDA as a tissue product under PHS 361 HCT/P (human cells, tissues and cellular and tissue-based products).
Study NCT04572035 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural Coaching
Description: behaviour change strategies (i.e., action planning, implementation intentions, relapse prevention, and goal setting)
Study NCT04572035 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-compassion psychoeducation
Description: self-compassion strategies (i.e., mindfulness, self-directed kindness meditations, and writing tasks)
Study NCT04572035 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: aerobic exercise program either delivered in a laboratory setting or via Zoom
Study NCT00141921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Open-label at a dose of 0.8 mg/kg (up to an intended dose of 50 mg) given once weekly by subcutaneous injection
Study NCT02337582 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Opportunistic Breast cancer screening
Description: Opportunistic breast screening offered to women attending clinics for non-breast health issues
Study NCT02337582 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: No breast screening was explicitly offered to women attending clinics for non-breast health issues, unless the health care provider felt that it was appropriate
Study NCT01750437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH1885L(Revaprazan)
Study NCT02658461 — intervention group
Intervention type: DRUG
Intervention: Trastuzumab
Description: Trastuzumab will be given on Day 1 of each 3-week cycle for a total of 18 cycles. Dosage will be according to the local labeling: 600 milligrams (mg) SC or 6 milligrams per kilogram (mg/kg) via IV infusion. For those assigned to the IV arm or if IV treatment is delayed >1 week, an initial loading/reloading dose of 8 mg/kg will be given instead. Due to the observational nature of this study, trastuzumab is not an investigational product but will be supplied in the MO22982 trial. Each route/device (SC single-use injection device, SC vial/syringe, IV infusion) will be observed in at least 12 episodes of care.
Study NCT01750437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole 20mg
Study NCT01750437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Study NCT01750437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study NCT00693264 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hoodia Gordonii
Description: 750 mg capsule will be taken one time
Study NCT00693264 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule to be taken one time
Study NCT00022477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-247550
Study NCT03797053 — intervention group
Intervention type: PROCEDURE
Intervention: Biological sample
Description: Biological sample performed :~* before treatment~* 1 months after the beginning of treatment~* every tumoral assessment
Study NCT00989599 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: compress of Chamomilla recutita infusion
Description: Patients with phlebitis due to peripheral intravenous infusion in anti-neoplasm chemotherapy were treated with a compress of Chamomilla recutita infusion for 20 minutes three times per day
Study NCT03113786 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CLARIX CORD 1K
Description: CLARIX CORD 1K is made from cryopreserved human umbilical cord, utilizing the patented CRYOTEK™ process. CLARIX CORD 1K is considered a Human Cells, Tissues \& Cellular and Tissue-based product (HCT/P) by U.S. FDA standards.
Study NCT00377416 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: rAAV2-CB-hAAT Gene Vector
Description: Participants will attend a 5-day inpatient visit, during which they will receive a series of injections consisting of one of four different doses of rAAV2-CB-hAAT.
Study NCT04318821 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Laser acupuncture
Description: Laser acupuncture is a non-invasive therapy that involves stimulation of traditional acupoints with low-intensity, non-thermal laser irradiation.
Study NCT04318821 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser acupuncture
Description: Laser acupuncture is a non-invasive therapy that involves stimulation of traditional acupoints with low-intensity, non-thermal laser irradiation.
Study NCT00989599 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: compress of lukewarm water
Description: Patients with phlebitis due to peripheral intravenous infusion in anti-neoplasm chemotherapy, in control group, were treated with a compress of lukewarm water for 20 minutes three times per day
Study NCT00991614 — intervention group
Intervention type: DEVICE
Intervention: EVOLUTION® Duodenal Stent
Description: EVOLUTION® Duodenal Stent
Study NCT01254305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levomilnacipran ER
Description: Drug: Levomilnacipran ER (40 -120 mg/day) Study drug is to be given orally, in capsule form, once daily for 8 weeks
Study NCT00382148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omalizumab
Description: SC repeating dose
Study NCT02048904 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Sitagliptin 100 mg/day for 3 months
Study NCT02048904 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 pill/day for 3 months
Study NCT02089685 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study NCT02089685 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PegIFN-2b
Description: Subcutaneous infusion
Study NCT02089685 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: IV infusion
Study NCT05287061 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multicomponent Psychological Program (MPP)
Description: Patients will receive health pills during hospital admission. This intervention will be brief for individual application, but without specific content for each person, protocolized in its content and tools, and with a cognitive-behavioral orientation. Its therapeutic objective is to provide the patient with immediate control strategies for negative emotions and some pattern of active and positive coping. Two months after hospital discharge, the patients will also receive a multicomponent psychological program of a group nature. Based on motivational interviewing and positive psychology, with two blocks: emotions and consolidation of intentions. Two individual sessions will be carried out at the beginning to be able to do individual orientation, plan the intervention protocol, determine the objectives, the group intervention, and the specific action packages that the patient will receive.
Study NCT01118312 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone Furoate monohydrate
Description: Intranasal mometasone, 1 spray (age \< 12 yr) or 2 sprays (age >= 12 yrs) each nostril once a day for 6 months
Study NCT01118312 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intranasal placebo spray
Study NCT03067818 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unaffected Transcranial Magnetic Stimulation
Description: Non-invasive brain stimulation to unaffected hemisphere site prior to practice
Study NCT03067818 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Affected Transcranial Magnetic Stimulation
Description: Non-invasive brain stimulation to affected hemisphere site prior to practice
Study NCT03067818 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control Transcranial Magnetic Stimulation
Description: Non-invasive brain stimulation to control site prior to practice
Study NCT00609960 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: clowns present
Description: clowns present during the proccess of induction of anesthesia
Study NCT06071611 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Oxygen-Ozone (O2-O3)
Description: Oxygen-Ozone (O2-O3) treatment by rectal insufflations for 5 weeks (3 sessions for week).
Study NCT06071611 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Oxygen (O2)
Description: Oxygen (O2) treatment by rectal insufflations for 5 weeks (3 sessions for week).
Study NCT06071611 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Placebo (Air)
Description: Air treatment by rectal insufflations for 5 weeks (3 sessions for week).
Study NCT04233125 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Core Decompression
Description: Core Decompression
Study NCT04233125 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Core Decompression
Description: Core Decompression
Study NCT04233125 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PMMA augmentation
Description: Polymethylmethacrylate (PMMA) augmentation
Study NCT01833871 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Three dimensional Power Doppler to the myometrial mass
Description: Trans-vaginal 3D power Doppler Ultrasonographic examination will be done for all participants prior to surgery. The ultrasonographic examination will provide data related to lesion size, lesion volume, vascular location (location), vascular index (VI), flow index (FI), and vascular-flow index (VFI). The region of interest will include the entire region of the uterine mass. The virtual organ computer aided analysis (VOCAL) software for the analysis of 3D power Doppler histograms will be used with computer algorithms to form indices of blood flow and vascularization. All data will be collected and compared with the post operative histopathology results.
Study NCT01833871 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Uterine artery Doppler
Description: uterine artery Doppler indices(RI,PI) are measured for all cases with myometrial mass
Study NCT04295590 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Frequency comparison
Description: One leg assigned to low-frequency low-intensity (3 days per week of 11 x 1 min @ 73% peak work rate interspersed with 1-minute periods of active recovery). The other leg assigned to high-frequency low-intensity (5 days per week of 11 x 1 min @ 73% peak work rate interspersed with 1-minute periods of active recovery).
Study NCT04295590 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensity comparison
Description: One leg assigned to low-frequency low-intensity (3 days per week of 11 x 1 min @ 73% peak work rate interspersed with 1-minute periods of active recovery). The other leg assigned to low-frequency high-intensity (3 days per week of 8 x 1 min @ 100% peak work rate interspersed with 1-minute periods of active recovery).
Study NCT00997971 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modilac Rose 1
Description: Infant formula used for non-breastfed children
Study NCT02874911 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General training
Description: Advanced spinocerebellar disease receive 12 weeks of coordinative training based on commercially available videogames (Product names: Nintendo Wii ®, Microsoft XBOX Kinect®).
Study NCT01288768 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Knee arthroscopy
Description: Knee arthroscopy within 4 weeks.
Study NCT01250821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Menopur
Description: The medication used in this study is the follicle-stimulating hormone highly purified human menopausal gonadotrophin (HP-HMG), Menopur, (Ferring a/s).~Stimulation with HP-hMG (Menopur) is started on day 2-5 of menstrual bleeding.The HP-hMG starting dose is calculated based on the nomogram predicting the threshold dose. The dose-range is from 75 IU/day to 187.5 IU/day.
Study NCT00706732 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AVX502
Description: 2 doses at 2e8 IU given at T=0 and T=4 weeks via the IM route
Study NCT00706732 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AVX502
Description: 2 doses at 2e8 IU given at T=0 and T=4 weeks given via the SC route
Study NCT00706732 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 doses of placebo given at T=0 and T=4 weeks via the IM route
Study NCT00706732 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 doses of placebo given at T=0 and T=4 weeks via the SC route
Study NCT00104871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Administered IV at the dose of 1.3 mg/m\^2 on a twice-weekly schedule for 2 consecutive weeks on days 1, 4, 8, and 11, followed by a 10 day rest period on days 12-21 (one cycle). In the absence of clinical progression, treatment continued for a minimum of 4 treatment cycles (or 12 weeks).
Study NCT05405829 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health education
Description: theoretical-practical hygienic-dietary training, with visual support and work materials where three specific interventions are explained: textures for solids and liquids, safety postures to reduce the risk of bronchial aspiration, and oral hygiene. In addition, tools are offered to caregivers so that they can identify situations of anxiety and overload, as well as guidelines for social support.